Independent effect of prior exacerbation frequency and disease severity on the risk of future exacerbations of COPD: a retrospective cohort study

[1]  J. Llorca,et al.  Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. , 2016, Archivos de bronconeumologia.

[2]  J. Llorca,et al.  Factors associated with lack of adherence to antenatal care in African immigrant women and Spanish women in northern Spain: the role of social risk factors in combination with language proficiency. , 2015, Midwifery.

[3]  Adam Hawkins,et al.  Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study , 2014, BMJ Open.

[4]  P. Bakke,et al.  Predictors of Exacerbations in Chronic Obstructive Pulmonary Disease - Results from the Bergen COPD Cohort Study , 2014, PloS one.

[5]  Stephanie A. Santorico,et al.  Prediction of acute respiratory disease in current and former smokers with and without COPD. , 2014, Chest.

[6]  Z. Tong,et al.  Predictors of exacerbation frequency in chronic obstructive pulmonary disease , 2014, European Journal of Medical Research.

[7]  J. Soriano,et al.  Spanish Guideline for COPD (GesEPOC). Update 2014 , 2014 .

[8]  Patrice Diot,et al.  Comorbidities of COPD , 2013, European Respiratory Review.

[9]  J. Wedzicha,et al.  Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease , 2013, BMC Medicine.

[10]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[11]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[12]  B. Celli,et al.  Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[13]  John Connett,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[14]  R. Hoogenveen,et al.  Association between lung function and exacerbation frequency in patients with COPD. , 2010, International journal of chronic obstructive pulmonary disease.

[15]  J. de Miguel Díez,et al.  [Comorbidities in COPD]. , 2010, Archivos de bronconeumologia.

[16]  A. M. Pastor,et al.  Calidad del registro en OMI-AP de los pacientes con ictus seguidos en atención primaria , 2010 .

[17]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[18]  J. Díez,et al.  [Comorbidities in COPD]. , 2010, Archivos de bronconeumologia.

[19]  A. Martínez Pastor,et al.  [Quality of records in OMI-AP of the patients with stroke followed in primary care]. , 2010, Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial.

[20]  Jiachun Lu,et al.  COPD in Chinese nonsmokers , 2009, European Respiratory Journal.

[21]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[22]  T. Seemungal,et al.  COPD exacerbations: defining their cause and prevention , 2007, The Lancet.

[23]  A. Hansell,et al.  COPD prevalence in a random population survey: a matter of definition , 2007, European Respiratory Journal.

[24]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[25]  N. Persaud,et al.  External validity: the neglected dimension in evidence ranking. , 2006, Journal of evaluation in clinical practice.

[26]  C. D. B. Lunar,et al.  Estudio de prescripción-indicación de inhibidores de la bomba de protones , 2006 .

[27]  G. Donaldson,et al.  COPD exacerbations · 1: Epidemiology , 2006, Thorax.

[28]  Cesar G Victora,et al.  Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study , 2005, The Lancet.

[29]  Paul A Estabrooks,et al.  Practical Clinical Trials for Translating Research to Practice: Design and Measurement Recommendations , 2005, Medical care.

[30]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[31]  A. Pont,et al.  Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study , 2004, Thorax.

[32]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.

[33]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[34]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[35]  M. Miravitlles,et al.  Factors Associated with Increased Risk of Exacerbation and Hospital Admission in a Cohort of Ambulatory COPD Patients: A Multiple Logistic Regression Analysis , 2000, Respiration.

[36]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[37]  H. Lamberts,et al.  The International Classification of Primary Care (ICPC): new applications in research and computer-based patient records in family practice. , 1996, Family practice.